|
|
|
25.02.26 - 13:33
|
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference (GlobeNewswire EN)
|
|
|
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Christopher U Missling, PhD, President & Chief Executive Officer, will present at the TD Cowen 46th Annual Health Care Conference on Monday, March 2nd, 2026 at 11:50 AM (ET)....
|
|
|
23.02.26 - 13:33
|
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors (GlobeNewswire EN)
|
|
|
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Dr. Axel Paeger, MD, MBA, MBI to its Board of Directors....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
08.01.26 - 13:33
|
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology (GlobeNewswire EN)
|
|
|
NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Wolfgang Liedtke, MD PhD, as Senior Vice President, Global Head of Neurology....
|
|
|
06.01.26 - 13:33
|
Anavex Life Sciences Receives FDA Feedback on Alzheimer′s Disease Program (GlobeNewswire EN)
|
|
|
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) had invited the Company to present the Company's Alzheimer's disease clinical trial results, reflecting the Agency's interest in the progress of Anavex's clinical development efforts....
|
|
|
|
|
|
|
18.12.25 - 13:33
|
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion (GlobeNewswire EN)
|
|
|
NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it has requested the European Medicines Agency (“EMA”) to re-examine its opinion on blarcamesine for the treatment of early Alzheimer's disease....
|
|
|
12.12.25 - 22:09
|
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer′s Disease (GlobeNewswire EN)
|
|
|
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today provides an update on the regulatory review in the EU for blarcamesine to treat early Alzheimer's disease....
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
